Pannex Therapeutics

Pannex Therapeutics is a private, preclinical-stage biotech founded in 2018 and based in San Diego. The company is building a platform around Pannexin 1 (Panx1) channel blockers, aiming to modulate a fundamental pathway of pathological ATP release that fuels inflammation and immune dysregulation. With a seasoned leadership team, the company is targeting broad applications in neurology and oncology, two areas with significant unmet need. Its approach represents a novel strategy to intervene in chronic inflammatory processes central to many diseases.

Platform for discovering selective small molecule blockers of the Pannexin 1 (Panx1) channel, a regulator of pathological ATP release that drives inflammation and immune dysregulation.

Competition includes other companies targeting purinergic signaling (e.g., P2X7 receptor antagonists). The field is emerging but could become crowded. Pannex's differentiation lies in its specific focus on the upstream Panx1 channel as a master regulator, rather than downstream receptors.